NCT04247594终止2 期
A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 6
- 试验地点
- 6
- 主要终点
- Treatment-emergent Adverse Events (AEs)
研究概览
简要总结
Study participants will undergo up to four periods of voxelotor administered orally at progressively higher dose levels from 1500 mg until either a maximum tolerated dose (MTD) or 3000 mg/day dose is reached, whichever occurs first
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female with SCD
- •Documentation of SCD genotype HbSS or HbSB0
- •Age 18 to < 60 years, inclusive
- •Hemoglobin ≥ 5.5 and ≤ 10.5 g/dL during Screening, and considered stable and close to Baseline by the Investigator
- •For participants taking HU, the dose in mg/kg must be stable for at least 90 days prior to signing the informed consent form (ICF) and with no anticipated need for dose adjustments during the study, in the opinion of the Investigator.
- •Participants, who if female and of child-bearing potential, agree to use highly effective methods of contraception or practicing abstinence from study start to 30 days after the last dose of study drug, and who if male, agree to use barrier methods of contraception or practice abstinence from study start to 30 days after the last dose of study drug
- •Participant has provided documented informed consent
排除标准
- •More than 10 VOCs within 12 months of screening that required a hospital, emergency room, or clinic visit
- •Female participant who is breast feeding or pregnant
- •Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received an RBC transfusion for any reason within 60 days of signing the ICF or at any time during the Screening Period
- •Hospitalized for sickle cell crisis or other vaso-occlusive event within 30 days prior to dosing (ie, a vaso-occlusive event cannot be within 30 days prior to dosing)
- •Screening laboratory test of alanine aminotransferase (ALT) > 4 × upper level of normal (ULN)
- •Clinically significant bacterial, fungal, parasitic, or viral infection which requires therapy, including acute bacterial infection requiring antibiotics
- •Known to be COVID-19 positive from within 3 weeks of screening through Day 1
- •Participants with active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
- •Severe renal dysfunction (estimated glomerular filtration rate < 30 mL/min/1.73 m2 at the Screening visit; calculated by the local laboratory to assess safety) or is on chronic dialysis
- •History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
- •History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
- •Unstable angina pectoris or myocardial infarction or elective coronary intervention
- •Congestive heart failure requiring hospitalization
- •Uncontrolled clinically significant arrhythmias
- •Pulmonary hypertension
- •Criteria related to ECG parameters:
- •PR interval > 220 msec in any participant
- •QRS interval > 120 msec or QT interval corrected using Fridericia's formula (QTcF) > 480 msec (both genders) in participants without bundle branch block
- •QRS interval > 120 msec in participants with newly (within 3 months) emerged bundle branch block
- •A participant with stable bundle branch block with or without stable cardiac disease may be enrolled; QRS interval > 120 msec and QTcF interval > 480 msec are acceptable in these participants.
- •Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
- •Participated in another clinical trial of an investigational agent or medical device within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent or medical device
- •Inadequate venous access as determined by the Investigator/site staff
- •Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent
- •Received erythropoietin or other hematopoietic growth factor treatment within 28 days of signing ICF or is anticipated to require such agents during the study
- •Ongoing or recent (within 2 years) substance abuse
- •Known allergy to voxelotor
- •Use of herbal medications (eg, St. John's Wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or moderate or strong CYP3A4 inducers
研究组 & 干预措施
Period 1
Experimental
1500 mg per day
干预措施: Voxelotor (Drug)
Period 2
Experimental
2000 mg per day
干预措施: Voxelotor (Drug)
Period 3
Experimental
2500 mg per day
干预措施: Voxelotor (Drug)
Period 4
Experimental
3000 mg per day
干预措施: Voxelotor (Drug)
结局指标
主要结局
Treatment-emergent Adverse Events (AEs)
时间窗: approximately 300 days
Treatment emergent AEs including SAEs
次要结局
- Number of Participants With an Hb Increase > 1 g/dL Compared to Baseline(approximately 200 days)
- Incidence Rate of VOCs(approximately 200 days)
- Number of Participants With Clinically Significant Abnormalities in Hb, Unconjugated Bilirubin, % Reticulocyte, Absolute Reticulocyte, and Lactate Dehydrogenase [LDH](approximately 200 days)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Voxelotor CYP and Transporter Cocktail Interaction StudySickle Cell DiseaseNCT05981365Pfizer44
已完成
2 期
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) AmyloidosisTTR-mediated AmyloidosisNCT01617967Alnylam Pharmaceuticals29
招募中
2 期
Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome2024-513313-13-00Curis Inc.70
已完成
2 期
Study of Infigratinib in Children With AchondroplasiaAchondroplasiaNCT04265651QED Therapeutics, Inc., a Bridgebio company84
进行中（未招募）
2 期
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)Lymphoma, Large B-Cell, Diffuse (DLBCL)NCT05406401Merck Sharp & Dohme LLC60